Digital makes its mark on cognition

Digital biomarkers of cognitive decline could be the antidote to the slop in the subjective tests on which clinical neurology programs often hinge. With proof of concept established in small clinical trials and bigger readouts on the way, data should emerge in the next year or two on the feasibility for digital readouts to replace standard endpoints in clinical trials for cognition.

The gold standard for assessing cognitive function in the clinic has been investigator-administered surveys that score patients on a battery of questions that assess memory, problem solving and other abilities. ...